

Non-Small Cell Lung Cancer (NSCLC) Market: Segmented: By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

<https://marketpublishers.com/r/NA74EC55BCB8EN.html>

Date: July 2023

Pages: 235

Price: US\$ 4,350.00 (Single User License)

ID: NA74EC55BCB8EN

Abstracts

Non-Small Cell Lung Cancer (NSCLC) Market By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery)and Region -Analysis of Market Size, Share & Trends for 2014 - 2019 and Forecasts to 2030

PRODUCT OVERVIEW

Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two main types of lung cancer NSCLC is the most common type of lung cancer accounting for approximately 85% of all lung cancers (IASLC, n.d.).Any epithelial lung cancer other than SCLC can be classified as NSCLC.NSCLC may be in the middle of the chest, but often also in other parts of the lung. Although NSCLCs are associated with smoking, they can also be found in patients who never have smoked. Adenocarcinomas are also common. Furthermore, chemotherapy and radiation therapy are fairly insensitive compared to SCLC.NSCLC comes from the central bronchial epithelial lung cells to the terminal alveoli. The histological type NSCLC coincides with the site of origin and reflects the variation in bronchial to alveoli respiratory epithelium. Whereas adenocarcinoma and bronchioloalveolar cancer typically originate from the peripheral lung tissue near central bronchuscommon symptoms include thoracic pain, wheezing, squatting, heartburn, chronic bronchitis, and loss of appetite, fatigue, shortness of

respiration, bone pain, trouble swallowing, and limb stubbornness.

MARKET HIGHLIGHTS

Non-Small Cell Lung Cancer (NSCLC) Market is expected to project a CAGR of 11.70% during the forecast period, 2021-2030

The Non-Small Cell Lung Cancer (NSCLC) market is anticipated to grow on the back of opportunities generated by the advent of the rising total number of lung cancer globally out of which Non-Small Cell Lung Cancer (NSCLC) holds a significant share. This has attracted the majority of the key leaders to focus on advancing therapeutics and increasing the efficiencies of the existing ones. This market is also driven by the existing status of lung cancer as the most widely occurring disease and the increase in the number of deaths it has caused. Also, an increase in the investments by the key leaders in research and developments and the introduction of Non-Small Cell Lung Cancer (NSCLC) therapeutics into the major market players is boosting the market globally.

GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: SEGMENTS

The global Non-Small Cell Lung Cancer (NSCLC) market is based on histology

Market Dynamics

Drivers

Rapid industrialization

Restraints

GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: KEY PLAYERS

Rozlytrek (Entrectinib)

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

Opdivo (Nivolumab)

Tagrisso (Osimertinib)

Vizimpro (Dacomitinib)

Portrazza (Necitumumab)

Imfinzi (Durvalumab)

Vitrakvi (Larotrectinib)

THE GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET REPORT ALSO CONTAINS AN ANALYSIS ON:

Global Non-Small Cell Lung Cancer (NSCLC) Market Segments

By histology

large cell carcinoma

adenocarcinoma

SCC or squamous cell carcinoma

By treatment

chemotherapy,

Radiation

surgery

Global Non-Small Cell Lung Cancer (NSCLC) Market Dynamics

Global Non-Small Cell Lung Cancer (NSCLC) Market Size

Supply & Demand

Current Trends/Issues/Challenges

Competition & Companies Involved in the Market

Value Chain of the Market

Market Drivers and Restraints

Reasons to Purchase this Report

Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market of various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

3-month post-sales analyst support.

Contents

1. EXECUTIVE SUMMARY

2. NON-SMALL CELL LUNG CANCER (NSCLC)

- 2.1. Product Overview
- 2.2. Market Definition
- 2.3. Segmentation
- 2.4. Assumptions and Acronyms

3. RESEARCH METHODOLOGY

- 3.1. Research Objectives
- 3.2. Primary Research
- 3.3. Secondary Research
- 3.4. Forecast Model
- 3.5. Market Size Estimation

4. AVERAGE PRICING ANALYSIS

5. MARKET DYNAMICS

- 5.1. Growth Drivers
- 5.2. Restraints
- 5.3. Opportunity
- 5.4. Trends

6. CORRELATION & REGRESSION ANALYSIS

- 6.1. Correlation Matrix
- 6.2. Regression Matrix

7. RECENT DEVELOPMENT, POLICIES& REGULATORY LANDSCAPE

8. RISK ANALYSIS

- 8.1. Demand Risk Analysis
- 8.2. Supply Risk Analysis

9. NON-SMALL CELL LUNG CANCER (NSCLC) INDUSTRY ANALYSIS

9.1. Porters Five Forces

- 9.1.1. Threat of New Entrants
- 9.1.2. Bargaining Power of Suppliers
- 9.1.3. Threat of Substitutes
- 9.1.4. Rivalry

9.2. PEST Analysis

- 9.2.1. Political
- 9.2.2. Economic
- 9.2.3. Social
- 9.2.4. Technological

10. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET

10.1. Market Size & forecast, 2019A-2030F

- 10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11. GLOBAL NON-SMALL CELL LUNG CANCER (NSCLC) MARKET: MARKET SEGMENTATION

11.1. By Regions

11.1.1. North America:(U.S. and Canada)

- 11.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)

- 11.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)

- 11.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)

- 11.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.1.5. The Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

- 11.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.2. By Histology Market Share (2020-2030F)

- 11.2.1. Large cells carcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.2.2. Adenocarcinoma, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

11.2.3. SCC or Squamous cell, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

11.3. By Treatment: Market Share (2020-2030F)

11.3.1. Chemotherapy, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%)
2020-2030F

11.3.2. Radiation, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.3.3. Surgery, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. COMPANY PROFILE

12.1. Rozlytrek (Entrectinib): Hofmann –La Roche

12.1.1. Company Overview

12.1.2. Company Total Revenue (Financials)

12.1.3. Market Potential

12.1.4. Global Presence

12.1.5. Key Performance Indicators

12.1.6. SWOT Analysis

12.1.7. Product Launch

12.2. Opdivo (Nivolumab): Bristol-Myers Squibb

12.3. Tagrisso (Osimertinib): AstraZeneca

12.4. Vizimpro (Dacomitinib): Pfizer

12.5. Portrazza (Nacitumumab): Eli Lilly and Company

12.6. Imfinzi (Durvalumab): AstraZeneca.

12.7. Vitrakvi (Larotrectinib): Bayer Healthcare

12.8. Other Prominent Players

Consultant Recommendation

The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

I would like to order

Product name: Non-Small Cell Lung Cancer (NSCLC) Market: Segmented: By histology (large cell carcinoma, adenocarcinoma and SCC or squamous cell carcinoma); By treatment (chemotherapy, radiation and surgery) and Region –Analysis of Market Size, Share & Trends for 2014 – 2019 and Forecasts to 2030.

Product link: <https://marketpublishers.com/r/NA74EC55BCB8EN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA74EC55BCB8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970